SHEZF (Shenzhen Hepalink Pharmaceutical Group Co) Total Liabilities: $694.1 Mil (As of Mar. 2026)


SHEZF Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
70 GF Score
Price $0.47
GF Value $0.55
! 7 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities?

Shenzhen Hepalink Pharmaceutical Group Co SHEZF 70 Total Liabilities is $694.1 Mil as of Mar. 2026. GuruFocus rates SHEZF with a GF Score™ of 70/100 and a GF Value™ of $0.55. The stock has 7 warning signs investors should review.

Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2026 was $694.1 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly Total Liabilities declined from Sep. 2025 ($660.14 Mil) to Dec. 2025 ($646.24 Mil) but then increased from Dec. 2025 ($646.24 Mil) to Mar. 2026 ($694.12 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual Total Liabilities declined from Dec. 2023 ($1,010.48 Mil) to Dec. 2024 ($706.17 Mil) and declined from Dec. 2024 ($706.17 Mil) to Dec. 2025 ($646.24 Mil).

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,190.85 1,205.81 1,010.48 706.17 646.24

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 718.11 699.54 660.14 646.24 694.12
SHEZF
70GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=561.304+(48.043+36.819
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0.074)
=646.2

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2361.393-1715.153
=646.2

Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=646.346+(9.307+38.388
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0.074)
=694.1

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2468.43-1774.311
=694.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $694.1 Mil mean?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Total Liabilities of $694.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Shenzhen Hepalink Pharmaceutical Group Co and its competitors.
Is Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Total Liabilities is $694.1 Mil. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities compare to ZTS and UTHR?
Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities of $694.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Shenzhen Hepalink Pharmaceutical Group Co's current Total Liabilities is $694.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Total Liabilities of $694.1 Mil. The stock's GF Value™ is $0.55, compared to a current price of $0.47 — trading 14.6% below its estimated fair value. The current Total Liabilities is $694.1 Mil. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Total Liabilities is $694.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of $0.47 is trading 14.6% below its estimated GF Value™ of $0.55.

Key valuation signals for SHEZF:

  • Total Liabilities: $694.1 Mil
  • GF Value™: $0.55 vs. price of $0.47 (14.6% below fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 09989:Hong Kong002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
70GF Score

Get the complete analysis for SHEZF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.55
GF Value